Klein,aber fein: Adeona Pharmaceuticals

Nun ist es März und wieder hoffen alle, daß die News über die Studie zum Alzheimer Mittelchen erstens kommen und dann natürlich zweitens positiv sind. Nach den beiden Ausbrüchen im Januar ging es ja leider stetig bergab. Leider hat sich unser Fachmann Chalifmann3 lange nicht mehr zu Wort gemeldet.

Denken wir an Human Genom Siences und drücken Adeona die Daumen.

 

Jo, er hat´s mal wieder geschafft! Gesperrt bis 19.03., und dann wahrscheinlich auch nur kurze Zeit wieder frei. 

Ich hoffe, dass es endlich wieder aufwärts geht, denn eigentlich gibt´s doch keinen Grund für den Absturz - außer der Tod des Senior Vice Presi Newsome kann´s doch nicht sein. 

 

 

http://www.nasdaq.com/aspxcontent/...;selected=AEN&SourceCode=PMZ

Adeona Receives Excellence in Science & Technology Award

-- Corp! Magazine Highlights Technology Leaders and Innovators --

ANN ARBOR, Mich., March 8, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it received a Corp! Magazine 2011 Digital, Science & Technology Award.  As an honoree, the Company is highlighted in the magazine's Special Edition e-Publication. The Corp! Magazine article featuring Adeona is available via the "Adeona in the News" section on the home page of the Company's website at www.adeonapharma.com.

SOURCE Adeona Pharmaceuticals, Inc.  

Die zulassung von Flupirtin soll zur debatte stehen,höre ich,aber ich habe im FDA Kalender nichts gefunden ....

Grummel  

da bist. Und wollen wir das Beste hoffen. Vielleicht haben die 10% Plus schon was damit zu tun.

 

Es kommt wieder Leben in unser Baby,bierro berichtet mir von einer positiven Studie zu Zinthionein,vielleicht gehts jetzt mal so richtig los,hm ?

MFG
Chali  

Lauf heute. Wie könnte jetzt das Kursziel sein?  

Bärenstark:

Hohes Vol. und z.Zt.  1,55  

Bei dem heutigen Kurs, der wohl durch die guten News herrührt, hätte man, wenn man in die Zukunft schauen könnte, Anfang März schön nachkaufen können. Na mal sehen, wie es weitergeht. Auch ohne wenn und aber und hätte und könnte.

 

mal eine interessante Einschätzung aus dem W:O von Dottore:
Zitat:

Man das geht ja gut ab. Ist das nur Spekulation, oder weiß da jemand schon mehr? Im zweiten Fall kann der Kurs locker die 3 $ durchstoßen.
Fibromyalgie ist ein Schmerzsyndrom, dessen Usache nicht geklärt ist und es gibt ein Myofasziales Schmerzsyndrom, das dem sehr ähnlich ist. In beiden Fällen und auch bei Rückenschmerzen ist dieses Medikament -Flupirtin- vielversprechend. In Deutschland unter dem Namen Trancopal zugelassen. Unverschämt teuer In der Retardform kostet eine Tablette über 3 € und kommt deshalb nur in Frage, wenn ich keine Kombination normaler Schmerzmedikamente hinbekomme

Sollte die Studie jetzt den Beweis erbringen, auch in der Fibromyalgie zu wirken, könnte es weltweit zum blockbuster werden. Zitat Ende.

Im Moment gerade am Tageshoch bei 1,81!!!!!!!  

Leute,es sieht verdammt gut aus,wobei ich mich momentan frage ob wir wegen Flupirtin oder wegen zinthionein explodieren ? Mann könnte aber mutmassen,dass Phase-3 Results der Studie ,die jetzt im März endet,bereits intern durchgesickert sind,bei dem Kursverlauf brauch man sich wohl nicht mehr fragen ob negativ oder positiv .....

MFG
Chali  

Einige im Yahoo-Board sehen eine ähnlich Rallye kommen wie bei Prana die letzten zwei Tage. Die hatten eine erfolgreiche Studie eines Parkinson-Medikaments veröffentlicht.

Kurs 1. Tag + 80 %, 2. Tag + 35 %  

Na super, das Teil heute schön auf 1,54 runtergebolzt. Minus 12 %. Grrr...  

Adeona Pharmaceuticals, Inc. announced today that Ashley I. Bush, M.D., Ph.D., has joined the Company's Scientific Advisory Board.

"Given my research in the area, I believe Adeona's product candidate for the dietary management of Alzheimer's disease, reaZin(TM), shows significant potential," said Ashley I. Bush, M.D., Ph.D. "I look forward to advising Adeona as they move their promising zinc-based product candidate through development for the treatment of Alzheimer's disease."

Ich kenne zwar Herrn Bush nicht persönlich, aber der Kurs mag ihn.

http://www.finanznachrichten.de/...e-involvement-of-met-008.htm 

 

 

 

ist der Mitbegründer von Prana!

Stimmen vom begeisterten Yahoo-Board:

This is big. It's almost validation we're on the right track. This bodes very well for the development of reaZin.
 
  To have the co-founder of Prana jump to our side speaks volumes about the path we're on.
 
  We are so close to success people.

Much more! If the chief scientific and cofounder of Prana joins Adeona`s board just 3 weeks before pivotal results will be published,
results should yet be unblinded ( as it`s end of March )...........Rocket leaves the station!!!!
 

http://messages.finance.yahoo.com/Stocks_(A_to_Z)/...rt=1#26035 

 

für den Beitrag. Sollte uns Mut machen weiter zu investieren.

 

Immer dasselbe, genau wie gestern: Hoch bis 1,95 und dann wieder runter. Öde!  

ANN ARBOR, Mich., March 28, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX:AEN - News), a developer of innovative medicines for serious central nervous system diseases, announced today that the ongoing clinical trial of its Trimesta™ (oral estriol) drug candidate has received an additional $409,426 in grant funding from the National Multiple Sclerosis Society (NMSS). The clinical trial is led by, Rhonda Voskuhl, M.D., Director, University of California Los Angeles (UCLA) Multiple Sclerosis Program, UCLA Department of Neurology. Adeona also announced that as of March 1, 2011, the clinical trial evaluating the reduction in the rate of relapses in female multiple sclerosis (MS) patients is 85% enrolled.

"We are very grateful to the NMSS for its continuous support of this MS program, from the preclinical development to the pilot and multi-center clinical trials, and now this current grant funding," said Dr. Voskuhl. "Their commitment to pursuing estriol for MS could potentially lead to a new, safe and effective oral therapy for this debilitating disease."

This ongoing clinical trial previously received a $5 million grant from the NMSS in partnership with the NMSS's Southern California chapter, with support from the National Institutes of Health, and $860,440 in grant funding through the American Recovery and Reinvestment Act. In November 2010, Adeona announced that it was awarded $244,480 under the Qualifying Therapeutic Discovery Project Program to support research and development expenses related to the Company's MS program.

The 150-patient, randomized, double-blind, placebo-controlled clinical trial of Trimesta is currently underway at 15 centers in the United States. Investigators are administering either Trimesta or matching placebo along with glatimer acetate (Copaxone®), an FDA-approved therapy for MS, to women between the ages of 18-50 who have been recently diagnosed with relapsing-remitting MS. With 127 out of 150 patients enrolled in the clinical trial by March 1, 2011, the Company anticipates full enrollment by the second half of 2011. Additional information regarding this multiple sclerosis clinical trial is available at http://www.clinicaltrials.gov/ct2/show/NCT00451204.

MFG
Chali  

sollten doch Vertrauen erwecken. Denn entgegen anderer, nur Sprechblasen produzierender Firmen, stehen hier Fakten im Vordergrund, die uns hoffen lassen, daß Adeona auf dem richtigen Weg ist.

 

As of December 31, 2010, Adeona had approximately $2.6 million in cash compared to approximately $2.7 million on December 31, 2009. As of February 28, 2011, Adeona had approximately $6.0 million in cash, including the net proceeds of approximately $3.7 million from the January of 2011 financing.


"We continued to make significant progress in the clinical development of our product candidates for Alzheimer's disease and multiple sclerosis during 2010. We anticipate reporting results from patients who have completed their 6 month follow-up in the Alzheimer's disease clinical study in April of 2011, and, if the clinical results are positive, we intend to further our commercialization efforts of reaZin as a prescription medical food. We also expect completion of enrollment in the multiple sclerosis clinical trial during the second half of 2011," stated James S. Kuo, M.D., M.B.A., Adeona's Chief Executive Officer.

"We achieved these clinical milestones while also increasing our revenues from various sources and carefully managing our operating expenses.


Dr. Kuo added, "With the addition of the net proceeds from the financing in January of 2011, we believe our current cash position should meet our planned operating needs for at least the next 12 months." 

 

 

momentan.
Es zeigt sich,wie richtig es war und ist,an der Aktie festzuhalten!  

heute.Die Kursentwicklung könnte nicht besser sein.
Charttechnisch siehts super aus!
Nach und nach verabschieden sich die schwachen Hände.


Adeona Reports 2010 Year End Financial Results

-- $3.2 Million Net Revenues Reported for the Year Ended December 31, 2010 --
-- Investor Conference Call Scheduled for 4:30pm (EDT) Today --

ANN ARBOR, Mich., March 31, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, today reported its financial results for the year ended December 31, 2010, as well as updates since the beginning of the 4th quarter.

Updates since the beginning of the 4th quarter include:

Clinical Programs

Alzheimer's Disease

   * Adoption of "reaZin" as the new trademark for Adeona's zinc and cysteine-based oral tablet (formerly called Zinthionein) currently under development as a prescription medical food for the dietary management of Alzheimer's disease and mild cognitive impairment.
   * Completion of the treatment phase of the pivotal clinical trial evaluating the zinc and cysteine-based product candidate, reaZin™ in patients with Alzheimer's disease and mild cognitive impairment. Results from this clinical trial are expected to be presented at the 63rd Annual Meeting of the American Academy of Neurology in April of 2011 by Lead Principal Investigator, Diana Pollock, M.D.


Multiple Sclerosis

   * Receipt of an additional $409,426 in grant funding from the National Multiple Sclerosis Society for the clinical trial evaluating Adeona's drug candidate, Trimesta™ (oral estriol).
   * Enrollment of 127 of 150 patients (85%) in the clinical trial evaluating Trimesta in women suffering from relapsing-remitting multiple sclerosis, as of March 2, 2011. The randomized, double-blind, placebo-controlled clinical trial is currently underway at 15 centers in the United States. We anticipate full enrollment by the second half of 2011.


Operations

   * Execution of an agreement for the sale of approximately 2.85 million shares of common stock at $1.40 per share to new institutional investors in a registered direct offering for gross proceeds of $4 million. Investors also received warrants to purchase approximately 1.42 million shares of common stock at an exercise price of $2.00 per share and are exercisable for a period of 13 months.
   * Appointment of George J. Brewer, M.D., the Morton S. and Henrietta Sellner Emeritus Professor of Human Genetics and Internal Medicine at the University of Michigan, as Senior Vice President of Research & Development, following the unexpected passing of David A. Newsome, M.D.
   * Expansion of the Scientific Advisory Board with the following appointments:
         o Ananda S. Prasad, M.D., Ph.D., a pioneer of zinc therapy with over 50 years of experience devoted to the field.
         o Ashley I. Bush, M.D., Ph.D., an expert in the research and development of new treatments for Alzheimer's disease based on the regulation of particular biometals.
   * Execution of an agreement with Dr. Prasad providing access to clinical data from a 50 patient, 12-month, randomized, double-blind, placebo-controlled clinical trial that evaluated the prevention of infections in the elderly who were treated with an oral zinc therapy or matching placebo. The results at 12 months demonstrated a 67% reduction in the incidence of infection between the two groups (88 infections in the placebo group versus 29 infections in the zinc treated group) (p < 0.001).
   * Termination of the dnaJP1 (hsp peptide) clinical development program as of March 31, 2011. While data from a Phase II clinical trial previously reported in November 2009 demonstrated safety and tolerability in patients with rheumatoid arthritis, the decision to discontinue this program was driven by strategic considerations as well as clinical and market potential.


Year Ended December 31, 2010 Financial Results

Total net revenues for the year ended December 31, 2010 were $3,164,512, compared to $103,089 for the year ended December 31, 2009. Total net revenues for the year ended December 31, 2010 consisted of $2,125,000 as a result of the Meda AB sublicense agreement of flupirtine for fibromyalgia during the second quarter of 2010, $550,553 of net laboratory revenues from the first full year of operations at Adeona Clinical Laboratory and $488,959 of grant revenues from the Qualifying Therapeutic Discovery Project Program to support Adeona's Alzheimer's disease and multiple sclerosis programs currently in clinical testing. Total net revenues for the year ended December 31, 2009 consisted of $103,089 of net laboratory revenues from Adeona Clinical Laboratory. Since purchasing Adeona Clinical Laboratory in July of 2009, the client base has increased and the in-house diagnostic testing services have been expanded to include a full array of microbiology testing.

Total costs and expenses for the year ended December 31, 2010 were $4,748,465, compared to $3,784,569 for the year ended December 31, 2009.

Research and development expenses increased to $1,579,891 for the year ended December 31, 2010, from $948,891 for the year ended December 31, 2009. This 66% increase is primarily the result of increased costs associated with the continued development of Adeona's product candidates, including outside manufacturing costs, consultant fees, license fees and patent costs. Research and development expenses also include a non-cash charge relating to stock-based compensation expense of $90,290 for the year ended December 31, 2010, compared to $188,166 for the year ended December 31, 2009.

General and administrative expenses decreased slightly to $2,700,951 for the year ended December 31, 2010, from $2,708,778 for the year ended December 31, 2009. General and administrative costs in 2009 included acquisition costs of $75,000 related to the purchase of Adeona Clinical Laboratory. General and administrative expenses also include a non-cash charge relating to stock-based compensation expense of $310,098 for the year ended December 31, 2010, compared to $135,770 for the year ended December 31, 2009.

Costs of laboratory services increased to $467,632 for the year ended December 31, 2010, from $126,900 for the year ended December 31, 2009. This increase is primarily the result of the increased costs associated with the expansion of the client base at Adeona Clinical Laboratory, including salary and supply costs.  The year ended December 31, 2010 included 12 months of costs, compared to the year ended December 31, 2009, which only included 6 months of costs after the acquisition in July of 2009.

The net loss for the year ended December 31, 2010 was $1,711,159, or $0.08 per share, compared to $3,731,405, or $0.18 per share, for the year ended December 31, 2009. The decrease in net loss is the result of increased revenues for the year ended December 31, 2010, that included license revenue, increased laboratory revenue and grant revenue.

SOURCE Adeona Pharmaceuticals, Inc.

Read more: http://www.nasdaq.com/aspx/...ear-end-financial-results#ixzz1ImOKjPHH  

ANN ARBOR, Mich., April 14, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. , a developer of innovative medicines for serious central nervous system diseases, announced today top-line results from its clinical study evaluating reaZin for the dietary management of Alzheimer's disease (AD) and mild cognitive impairment (MCI). The clinical study met the primary outcome of increasing serum zinc and decreasing serum free copper. In addition, secondary outcomes of mental status as measured by three standardized cognitive tests all favored the treatment group versus the placebo group.

http://www.finanznachrichten.de/...secondary-outcome-of-reazi-008.htm

So, also die Prognosen wurden bestätigt, der Kurs hat sich allerdings im Vorfeld wenig bewegt. Was sagen die Biotech-Spezialisten dazu?

Ist überhaupt noch jemand hier?  

Adeona Zinc Tab Fails to Aid Alzheimer's Patients 

Unter diesem reißerischen Aufmacher hat der berüchtigte Kolumnist Adam Feuerstein von TheStreet die Wirksamkeit von reaZin in Abrede gestellt.

Und was der Kurs machte, wissen nun. Ich denke, sie kommt wieder.

http://www.thestreet.com/story/11083931/1/...mers-patients.html 

 

 

 

ich mag nicht glauben, dass ein "berüchtigter Kolumnist" einen Kusrsturz von ca. 50% verursachen kann....
Da muss doch mehr dahinterstecken...